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Abstract: Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related 
to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens 
including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin 
is currently FDA-approved for the treatment of complicated skin and skin-structure infections. 
Recently, two randomized clinical trials demonstrated the efficacy and safety of telavancin 
compared to vancomycin for the treatment of nosocomial pneumonia. Overall, telavancin has 
a favorable safety profile. However, mild gastrointestinal disturbances and reversible increases 
in serum creatinine were observed in clinical studies. Additional clinical studies are needed to 
evaluate telavancin’s efficacy and safety in comparison to other antistaphylococcal agents for 
the treatment of infections such as bacteremia and endocarditis.
Keywords: telavancin, MRSA, hospital-acquired pneumonia, health care-associated pneumonia, 
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Introduction
Nosocomial pneumonia describes hospital-acquired pneumonia (HAP), health care-
associated pneumonia (HCAP), or ventilator-associated pneumonia (VAP); all of 
which are delineated primarily based on the time of onset and etiology of infection. 
HAP, pneumonia that occurs greater than 48 hours after admission, is the second most 
common nosocomial infection in the United States (US).1 HCAP refers to pneumonia 
acquired outside of the hospital by patients with certain risk factors for infection by 
pathogens of a nosocomial origin. These risk factors include hospitalization in an acute 
care facility for two or more days in the previous 90 days; residence in a nursing home 
or long-term care facility; previous intravenous antibiotic therapy, chemotherapy, or 
wound care within the past 30 days of the current infection; or hemodialysis in the 
hospital or clinic. In contrast, VAP is pneumonia that occurs at least 48 hours after 
endotracheal intubation.1 Both HAP and VAP remain contributors to poor patient 
outcomes despite advances in antibiotic therapy and the implementation of preventa-
tive measures.1 HAP has an average incidence of 5 to 10 cases per 1000 hospitalized 
patients, and an estimated attributable mortality of up to 50%.1,2 A HAP diagnosis 
increases the length of hospitalization by an average of 7 to 9 days per patient, cost-
ing a reported excess of US$40,000 per patient.3,4
HAP can be caused by a variety of organisms including aerobic Gram-negative 
bacilli and Gram-positive cocci, particularly methicillin-resistant Staphylococcus 
aureus (MRSA).1,2 HAP caused by S. aureus has become a major epidemiological 
focal point, considering the rapid emergence of resistant strains with limited treatment 
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options and their impact on mortality. In an analysis of a 
large US inpatient database, S. aureus was found to be the 
only pathogen among those causing nosocomial pneumonia 
to be associated with a significant increase in mortality.2 
The same study showed that patients infected with MRSA 
were more likely to receive inappropriate antibiotic therapy.2 
Inadequate therapy is associated with both an increase in 
pneumonia treatment failure rates and mortality.1
Risk factors for HAP have primarily been extrapolated 
from patients diagnosed with VAP. These risk factors are 
categorized as modifiable and nonmodifiable (Table 1).1,5,6 
Identifying and addressing modifiable risk factors could 
potentially aid in HAP management. These risk factors may 
also be important to consider when selecting antimicrobial 
therapy. The time of onset of clinical signs of pneumonia 
serves as a helpful indicator in determining likely pathogens 
and potential patient outcomes associated with HAP. Early-
onset HAP (occurring within the first 4 days of hospital 
admission) is more likely to be caused by pathogens suscep-
tible to antimicrobial therapy.1 In comparison, late-onset HAP 
(occurring 5 days or more within current hospitalization) is 
more likely due to multidrug-resistant (MDR) pathogens.1 
Late-onset HAP and VAP caused by MDR pathogens is 
associated with increased morbidity and mortality.1
Consequences of HAP are further compounded by the 
limited antimicrobial treatment options available to combat 
this growing health care problem. Currently, vancomycin and 
linezolid are the only recommended therapies for HAP caused 
by MRSA.1 Even more concerning is that recent evidence 
suggests that MRSA isolates with a minimum inhibitory 
concentration (MIC) of 2 µg/mL do not respond as well to 
vancomycin as those isolates with an MIC of # 0.5 µg/mL.7 
The serious consequences of HAP coupled with limited 
treatment options emphasize the need for more available 
antistaphylococcal agents for the treatment of this infection.
This article provides an overview of telavancin, includ-
ing its clinical efficacy and safety profile, and evaluates its 
potential role in the treatment of nosocomial pneumonia 
caused by MRSA.
Overview of telavancin
Telavancin (VibativTM; Theravance, San Francisco, CA, USA) 
is a bactericidal, lipoglycopeptide antibiotic that is structurally 
related to vancomycin.8 It is an intravenous, semi-synthetic 
product with concentration-dependent, antimicrobial activity 
against Gram-positive aerobic and anaerobic bacteria.9 Tela-
vancin’s mechanism of action is twofold.10 It inhibits bacterial 
cell wall synthesis by interfering with the polymerization and 
cross-linking of peptidoglycan. Also, telavancin binds to the 
bacterial membrane and disrupts membrane barrier function. 
Telavancin has been associated with a tenfold greater pepti-
doglycan synthesis inhibitory activity in intact MRSA cells 
compared to vancomycin.11 In initial clinical trials and surveil-
lance studies, telavancin demonstrated in vitro activity against 
organisms that commonly cause skin and skin-structure 
infections and Gram-positive bacteria that cause pneumonia, 
including Staphylococcus spp., Streptococcus spp., and some 
Enterococcus spp.12 Telavancin does not exhibit appreciable 
activity against the most common type of vancomycin-
resistant enterococci, Van A-producing strains.12–14 However, 
telavancin may have some activity against Van B- and Van 
C-producing strains, depending on the free drug concentra-
tions achieved.12–14 Currently telavancin is approved by the 
US Food and Drug Administration (FDA) for the treatment 
of adult patients with complicated skin and skin-structure 
infections (cSSSI) caused by susceptible Gram-positive 
bacteria. A summary of telavancin dosing recommendations, 
considerations in special populations, and potential interac-
tions is provided in Table 2.
Activity against Staphylococcus aureus
Telavancin demonstrated in vitro bactericidal activity against 
methicillin-susceptible S. aureus (MSSA) with an MIC90 
(minimum inhibitory concentration required to inhibit 
the growth of 90% of organisms) of 0.12–1 µg/mL com-
pared to 1–2 µg/mL for vancomycin.10,15 Similar in vitro 
  activity against MRSA was also observed with an MIC90 of 
0.25–1 µg/mL compared to 1–2 µg/mL for vancomycin.9,10,16 
Currently, the Clinical and Laboratory Standards Institute 
(CLSI) has not published susceptibility breakpoints for 
telavancin. However, the FDA-approved MIC breakpoint 
for S. aureus, including MRSA, is #1 µg/mL using the 
broth   dilution method. Although   intermediate and resistant 
Table 1 Risk factors for hospital-acquired pneumonia1,5,6
Modifiable risk factors Nonmodifiable risk factors
•  Intubation
•    Duration of mechanical  
ventilation
•  Aspiration
•    Body position (supine  
versus semi-recumbent)
•  Enteral feeding
•    Modulation of colonization 
(eg, decontamination)
•  Stress ulcer prophylaxis
•  Transfusions
•  Hyperglycemia
•  Extremes of age
•    Chronic lung disease (especially 
bronchitis, chronic obstructive 
pulmonary disease and asthma)
•  Abdominal or thoracic surgery
•  Intubation
•    Duration of mechanical 
ventilation
•  Immunosuppression
•  Prior antimicrobial use
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breakpoints have not been established, the manufacturer 
recommends that isolates yielding results other than suscep-
tible be subjected to additional testing.17
Pharmacokinetics
In healthy young adults, telavancin demonstrated linear phar-
macokinetics following the IV administration of single doses 
ranging from 5 to 12.5 mg/kg and multiple doses ranging 
from 7.5 to 15 mg/kg once daily for up to 7 days.18 Steady-
state concentrations were achieved by the third daily dose. At 
24 hours post-infusion, serum concentrations from subjects 
given telavancin exceeded the MIC90 for MRSA and penicillin-
resistant Streptococcus pneumoniae strains, suggesting that 
telavancin is an effective once-daily antibacterial agent.
Telavancin has a small volume of distribution (0.115 L/kg), 
with approximately 90 to 95% of the drug being bound to 
albumin. In pharmacokinetic studies, its elimination half-life 
(t1/2) was 7.5 hours in healthy adults who received a single 
dose and 9.11 hours in adults who received multiple doses, 
respectively.11,19 Telavancin primarily undergoes renal elimi-
nation and 65% to 72% of the drug is excreted unchanged 
after several doses.18
Though controversial, drug concentrations in epithelial 
lining fluid (ELF) have been used to evaluate drug pen-
etration into the pulmonary tissues.20 The intrapulmonary 
d  istribution of telavancin (10 mg/kg IV every 24 hours) was 
evaluated in 20 healthy individuals.21 Throughout the dosing 
interval, telavancin achieved concentrations up to eightfold 
and 85-fold in ELF and alveolar macrophages, respectively, 
above the MIC90 for MRSA (0.5 µg/mL). It was also noted 
that pulmonary surfactant did not affect the in vitro antibac-
terial activity of telavancin. Using these 20 subjects, Monte 
Carlo simulation and population pharmacokinetic modeling 
were performed to evaluate telavancin’s penetration into ELF. 
Investigators reported a median ELF area under the curve 
(AUC) that was approximately 75% of the free plasma AUC.22 
In comparison, vancomycin concentrations in lung tissue 
ranges from 5% to 41% of serum concentrations.23–25 Epithe-
lial lining fluid penetration in critically injured patients was 
highly variable, with an overall serum to ELF ratio of 6:1.26 
These observations suggest that penetration of vancomycin 
into pulmonary tissue and ELF is poor.25,26
Pharmacodynamics
Against S. aureus, telavancin exhibits concentration-
  dependent bactericidal activity with a post-antibiotic effect 
of 1 to 4 hours.12,27,28 The AUC/MIC ratio has been identified 
as the pharmacodynamic marker correlating to the drug’s 
efficacy against S. aureus.21 An in vitro study demonstrated 
that the maximal killing against S. aureus was achieved at an 
AUC/MIC ratio of 404.29 Alternatively, the lowest AUC/MIC 
ratio yielding no bacterial regrowth was 50. In order to 
Table 2 Telavancin dosing, use in special populations, and interactions17,19,30,41–46
Dosing 
Recommended dosing in normal renal function:
10 mg/kg intravenously (Iv) every 24 hours administered as a 1-hour infusion
Recommended dosing modification in renal impairment:
Creatinine clearance (ClCr) Recommended dosage adjustment
30–49 mL/min Administer 7.5 mg/kg Iv every 24 hours
10–29 mL/min Administer 10 mg/kg Iv every 48 hours
,10 mL/min Dosing recommendation not available
Hemodialysis Dosing recommendation not available; about 6% of drug removed during four-hour session
Special populations 
Sex and age: No clinical impact on the pharmacokinetic disposition of telavancin
Pregnancy: FDA pregnancy category C
Black box warning for potential risk of abnormal fetal development (ie, reports of increased rates of digit and limb malformations in animal offspring)
Prescribers encouraged to register pregnant women receiving telavancin or women may enroll themselves into a pregnancy exposure registry created 
by Theravance
Interactions 
Drug–drug Interactions: No clinically significant interactions have been reported with the concomitant use of telavancin and other drugs
Drug–laboratory test interactions:
Coagulation tests affected Coagulation tests not affected
•  INR (International Normalized Ratio) •  Fibrinogen level
•  PT (Prothrombin time) 
•    aPTT (activated partial thromboplastin time)
•  Thrombin time 
•  Heparin level
•  ACT (Activated Clotting time) •  D-dimer
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  minimize the emergence of resistance, it has been suggested 
that the telavancin AUC/MIC ratio remain above 50.30
Animal models of pneumonia
The efficacy of telavancin and vancomycin against MRSA 
strains with vancomycin MICs $ 1 µg/mL was compared in a 
neutropenic murine model of pneumonia.31 Mice were admin-
istered antibiotic doses designed to simulate the area under 
the concentration-time curve (AUC) observed in humans 
given telavancin 10 mg/kg IV every 24 hours or vancomycin 
1 g IV every 12 hours. Thirteen clinical MRSA isolates (one 
vancomycin-susceptible, two vancomycin-heteroresistant, 
and four vancomycin-intermediate) were tested after 24 hours 
and seven isolates (one vancomycin-heteroresistant, and 
four vancomycin-intermediate) were tested after 48 hours 
of exposure to the drug. Efficacy was expressed as the 24 or 
48 hour change in lung bacterial density from pretreatment 
counts. During both time points, similar colony-forming 
unit (CFU) reductions were demonstrated for telavancin and 
vancomycin against MRSA isolates with vancomycin MICs 
of 2 µg/mL or less. Both telavancin and vancomycin demon-
strated similar efficacy following 24 and 48 hours of exposure 
against the vancomycin-heteroresistant strains tested. Against 
vancomycin-intermediate isolates, telavancin reduced bacte-
rial burdens more than vancomycin for one of four isolates 
after 24 hours and for three of four isolates after 48 hours.
Another study compared telavancin to vancomycin 
and linezolid in a neutropenic murine model of MRSA 
  pneumonia.32 The MICs of telavancin, vancomycin, and lin-
ezolid against MRSA were 0.5, 1, and 1 µg/mL,   respectively. 
Mice were administered antibiotic doses that closely approxi-
mated human exposures at doses of 5 and 10 mg/kg IV 
for telavancin, 1 g IV every 12 hours for vancomycin, and 
600 mg IV every 12 hours for linezolid.32,33 Mice treated 
with telavancin demonstrated a significantly greater reduc-
tion in lung bacterial titers at 48 hours compared to the 
mice treated with vancomycin or linezolid.
Clinical studies: ATTAIN 1  
and ATTAIN 2
The efficacy of telavancin for the treatment of HAP, HCAP, 
and VAP due to Gram-positive pathogens, specifically 
MRSA, was evaluated in two identical randomized, 
  multinational, noninferiority trials.34 Eligible patients 
were adult nonpregnant females or males who showed 
clinical signs and symptoms consistent with nosocomial 
  pneumonia. Patients were required to have specific signs and 
symptoms of pneumonia, radiographic findings consistent 
with pneumonia, and a sufficient respiratory specimen 
for microbiologic   evaluation. Exclusion criteria included 
prior receipt of potentially effective antibiotic therapy for 
Gram-positive pneumonia, Gram stain or culture revealing 
only Gram-  negative bacteria, presence of certain pulmonary 
diseases (lung cancer, active tuberculosis, cystic fibrosis, 
or granulomatous disease), uncompensated heart failure, 
absolute neutrophil count , 500 cells/mm3, and baseline 
QTc interval greater than 500 milliseconds.
Patients were randomized in a 1:1 fashion to receive 
either telavancin, 10 mg/kg IV every 24 hours, or vanco-
mycin, 1 g IV every 12 hours, for 7 to 21 days. Telavancin 
dosage adjustments were permitted in patients with crea-
tinine clearance (ClCr) of 50 mL/min or less. Vancomycin 
regimens were monitored and adjusted according to insti-
tutional policy at each site. The primary end point was 
clinical response (cure or failure) at follow-up/test-of-cure 
visit in the all-treated (AT) and clinically-evaluable (CE) 
  populations, with a prespecified noninferiority margin 
of 20%. The AT population included patients who were 
randomized and received at least one dose of the study drug. 
The CE population included patients in the AT population 
who were protocol-adherent or who died from the HAP 
episode after study day 3. Results of the two identical 
studies were pooled for analysis. Secondary outcomes such 
as clinical response rate by identified pathogen, mortality, 
and safety parameters were also evaluated.
Of the 1532 patients randomized, 1,503 received at least 
one dose of the study drug (telavancin, n = 749;   vancomycin, 
n = 754; AT population). A total of 654 patients were 
included in the CE population (telavancin, n = 312; vanco-
mycin, n = 342). Patients in both groups were comparable in 
terms of baseline and demographic variables. More than half 
of the patients in both groups were aged 65 years or older 
and more than half of the patients were in the intensive care 
unit at baseline. About 25% of patients in both groups had 
APACHE II scores greater than 20. Common comorbidities 
included diabetes, chronic obstructive pulmonary disease, 
and renal failure (acute and/or chronic). About one-third of 
patients in both groups had a ClCr of 50 mL/min or less. More 
than half of the patients in both groups received previous 
antibiotics for greater than 24 hours.
Monomicrobial pneumonia caused by S. aureus was 
present in a total of 298 patients, and MRSA was the 
major (60%) pathogen isolated from the respiratory tract. 
Mixed (Gram-positive and Gram-negative) infections were 
present in 27% of patients. Bacteremia was diagnosed 
in   approximately six percent of patients. The MIC90 for 
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both MSSA and MRSA was 0.5 µg/mL for telavancin and 
1 µg/mL for vancomycin. In those patients for which van-
comycin serum concentration monitoring was performed 
(n = 226), the mean trough was $5 µg/mL in 94% of patients 
and $10 µg/mL in 66% of patients.
In the AT population, cure rates were 58.9% for 
telavancin and 59.5% for vancomycin (95% confidence 
  interval [CI]: −5.6% to 4.3%). In the CE population, cure 
rates were 82.4% for telavancin and 80.7% for vancomycin 
(95% CI: −4.3% to 7.7%). Based on these results, telavan-
cin’s noninferiority to vancomycin was demonstrated.
In secondary analysis, clinical response in patients with 
pneumonia due to MRSA with or without other patho-
gens was also similar between the two treatment groups. 
However, treatment with telavancin was associated with 
higher cure rates in patients with MSSA (87.9% versus 
75%; 95% CI: −4.2% to 28.8%) and monomicrobial MRSA 
infection (81.8% versus 74.1%; 95% CI: −3.5% to 19.3%). 
Similarly, higher cure rates with telavancin were observed 
among patients infected with S. aureus with a vancomycin 
MIC $ 1 µg/mL (87.1% versus 74.3%; P = 0.03). Cure 
rates were lower for telavancin in patients with mixed 
infections (66.2% versus 79.4%; 95% CI: −26.9% to 3.2%). 
However, cure rates were similar between treatment 
groups in patients with mixed infections who received 
adequate Gram-negative antimicrobial coverage (63.2% 
versus 66.7%; 95% CI: −28.9% to 25.7%). There were 
no significant differences in mortality between treatment 
groups (20% for telavancin versus 18.6% for vancomycin, 
95% CI: −2.6% to 5.3%).
Safety
More patients experienced serious adverse events that 
lead to drug discontinuation in the telavancin group com-
pared to the vancomycin group (8% versus 5%). The most 
common adverse effects reported were nausea, anemia, 
hypokalemia, diarrhea, and constipation. Clinically sig-
nificant increases in serum creatinine were more frequent 
among the telavancin group compared to the vancomy-
cin group (16% versus 10%). Drug-related increases in 
serum creatinine associated with telavancin were mild 
and reversible after drug discontinuation. Prolongation 
of the QTc interval . 60   milliseconds occurred in 8% of 
telavancin-treated patients and 7% of vancomycin-treated 
patients. A maximum QTc   interval . 500 milliseconds 
occurred in 2% of patients in each group, and no patients 
experienced arrhythmias attributable to a prolonged QTc 
interval.
Limitations of the ATTAIN studies
Due to variations by country in the standard of care for 
pneumonia diagnosis, a limited number of patients in the 
ATTAIN studies underwent semi-invasive procedures 
such as bronchoalveolar lavage (BAL). Therefore, deter-
mination of the exact microbial pathogen in these studies 
may be less reliable. Respiratory tract samples (invasive 
or noninvasive) were obtained in approximately 30% of 
patients overall.
Authors reported that the majority of patients achieved 
“adequate” mean vancomycin serum concentrations 
(5–15 µg/mL). However, for the treatment of health care-
associated pneumonia (including HAP and VAP), the 
recommended trough goal is 15–20 µg/mL.1,35,36 This 
trough goal should be considered for invasive infec-
tions such as HAP, and may increase the likelihood of 
achieving the target AUC/MIC ratio of 400 (when the 
MRSA MIC is , 2 µg/mL).35 Furthermore, since van-
comycin troughs ,10 µg/mL have been associated with 
the emergence of resistance, this should generally be 
avoided.35,37 In the ATTAIN studies, telavancin was likely 
compared to suboptimal vancomycin therapy suboptimal 
vancomycin therapy as evidenced by only   evidenced by 
only 66% of patients with a trough $10 µg/mL. A com-
parison of telavancin to dose-optimized vancomycin could 
serve to further validate the findings of the ATTAIN 
studies.
Clinical utility of telavancin
Telavancin provides advantages in the treatment of noso-
comial pneumonia due to MRSA compared to other 
antistaphylococcal agents. It exhibits rapid bactericidal 
activity, whereas vancomycin demonstrates relatively slow 
bactericidal activity. Additional advantages over vancomycin 
include once-daily dosing, the lack of serum concentra-
tion monitoring, and a low incidence of infusion-related 
reactions. Telavancin lacks clinically relevant drug interac-
tions, which may be an advantage over linezolid. However, 
telavancin is available only as an intravenous preparation. 
Also, telavancin has demonstrated in vitro and clinical 
efficacy in the treatment of pneumonia, an advantage over 
daptomycin.
Higher vancomycin MICs in MRSA are correlated with 
a greater likelihood of treatment failure.23,35,36 The fact that 
MICs have continued to increase in S. aureus strains high-
lights the need for additional effective antibacterial agents.34 
Though a secondary outcome in the ATTAIN studies, 
higher cure rates with telavancin were observed in patients 
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infected with MRSA with a vancomycin MIC $ 1 µg/mL. 
This preliminary evidence suggests that telavancin may 
play a role in treating this subset of patients. However, this 
requires further study.
Results of  two retrospective analyses and one prospective 
study suggest that linezolid is superior to vancomycin for 
the treatment of MRSA nosocomial pneumonia.38,39 In light 
of these findings, subsequent studies should evaluate the 
efficacy of telavancin compared to linezolid for MRSA 
nosocomial pneumonia. Furthermore, comparing telavancin, 
linezolid, and dose-  optimized vancomycin simultaneously 
may provide additional insight into the agent of choice for 
this indication.
Though there are benefits to telavancin use, additional 
research is necessary in some areas. At the present time 
evidence does not support the use of telavancin in patients 
with severe renal insufficiency, therefore limiting its use 
to patients with a ClCr . 10 mL/min. The acquisition cost 
of telavancin may limit its use in health care facilities. 
Although pharmacoeconomic analysis is not yet avail-
able, the reported average wholesale price of telavancin 
is approximately $150 per day compared to $20 per day 
for vancomycin.40   Additional clinical studies are needed 
to evaluate the efficacy of telavancin for the treatment of 
other serious Gram-positive infections, such as bacteremia 
and endocarditis, as well.
Conclusion
In the setting of limited options for the treatment of noso-
comial pneumonia due to MRSA, telavancin represents an 
effective alternative to standard therapy. Telavancin was 
associated with higher cure rates among MRSA strains with 
a vancomycin MIC $ 1 µg/mL, providing a potential role 
to be further explored. Overall, telavancin is well tolerated, 
with the most commonly experienced side effects being 
gastrointestinal intolerance and mild, reversible elevations 
in serum creatinine.
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